Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00190931 · ClinicalTrials.gov registry record · Phase 4
A Functional Outcomes Study With Atomoxetine-Hydrochloride and Placebo in Adults With Attention-Deficit/Hyperactivity Disorder
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 400
- Enrollment target
NCT00190931 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 400 participants.
The verdict
NCT00190931, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 400 participants
- Enrollment target
Study Summary
The overall primary objective of this study is to test the hypothesis that, compared with placebo,administration of atomoxetine will result in an improved work productivity.
Interventions
- DRUG placebo
- DRUG Atomoxetine Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2003-11 |
| Est. Completion | 2005-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00190931
The ClinicalTrials.gov registry entry for NCT00190931 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00190931 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00190931 about?
NCT00190931 is a clinical study titled "A Functional Outcomes Study With Atomoxetine-Hydrochloride and Placebo in Adults With Attention-Deficit/Hyperactivity Disorder". The overall primary objective of this study is to test the hypothesis that, compared with placebo,administration of atomoxetine will result in an improved work productivity.
What is the current status of trial NCT00190931?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 400 participants. The study started on 2003-11. Estimated completion is 2005-07.
What interventions are being tested in trial NCT00190931?
The interventions under investigation include: placebo (DRUG), Atomoxetine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00190931?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.